SCHEMBL7366311

SCHEMBL7366311

COC(=O)C1(S(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 15/20 0.78
MMP1 P03956 14/20 0.78
MMP9 P14780 14/20 0.78
MMP13 P45452 14/20 0.78
ADAMTS4 O75173 1/20 0.78
MMP2 P08253 1/20 0.78
MMP3 P08254 1/20 0.78
MMP7 P09237 1/20 0.78
MMP8 P22894 1/20 0.78
MMP14 P50281 1/20 0.78
ADAMTS5 Q9UNA0 1/20 0.78
ALDH1A1 P00352 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
HTT P42858 2/20 0.67
LMNA P02545 1/20 0.67
GAA P10253 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
CYP3A4 P08684 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7410572 0.90 ALDH1A1 (0.90) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL7366360 0.89 ADAM17 (0.81) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL7409543 0.88 ADAM17 (1.00) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL7623960 0.81 ADAM17 (0.76) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL6567121 0.81 MMP1 (0.80) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL6565432 0.80 CYP3A4 (0.84) ADAM17MMP1MMP9MMP13ALDH1A1
SCHEMBL7953288 0.80 MEN1 (0.75) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL14995881 0.79 MMP9 (0.52) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL6567122 0.79 MMP1 (1.00) ADAM17MMP1MMP9MMP13ADAMTS4
SCHEMBL7405314 0.79 SMN1; SMN2 (0.76) ADAM17MMP1MMP9MMP13ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252143-A1 METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES American Cyanamid Company (US) 2002-10-30 EP disclosed
US-20020099035-A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives WYETH HOLDINGS CORPORATION 2002-07-25 US disclosed
WO-2001055112-A1 METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES AMERICAN CYANAMID COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099035-A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives MMP25, ADAMTS5, MMP9 ADAM17 4/4885MMP1 14/4885MMP9 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.